Tumor microenvironment changes tumor cell sensitivity to action of energy metabolism modifiers

O N Pyaskovskaya1, D L Kolesnik1, I V Prokhorova1

  • 1R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv 03022, Ukraine.

Experimental Oncology
|September 30, 2020
PubMed
Abstract

Insights

Sodium dichloroacetate (DCA) and metformin (MTF) did not inhibit Lewis lung carcinoma (LLC) growth or metastasis in vivo. This combination therapy showed no significant impact on tumor bioenergetics or immune cell populations, suggesting limited therapeutic potential.

Area of Science:

  • Oncology
  • Cancer Metabolism
  • Drug Discovery

Background:

  • Tumor cells exhibit distinct bioenergetics compared to normal cells, justifying the search for antitumor drugs targeting metabolic pathways.
  • Sodium dichloroacetate (DCA) and metformin (MTF) have shown potential in modifying tumor metabolism.
  • Previous in vitro studies indicated enhanced cytotoxic/cytostatic effects of DCA combined with MTF against Lewis lung carcinoma (LLC) cells.

Purpose of the Study:

  • To investigate the in vivo antitumor efficacy of combining DCA and MTF against LLC.
  • To evaluate the impact of this combination therapy on tumor growth, metastasis, and key cellular and metabolic markers.

Main Methods:

  • LLC/R9 cells were inoculated into mice, followed by treatment with MTF alone or in combination with DCA.
  • Tumor growth and metastasis were assessed, alongside mitochondrial electron transport chain function using electron paramagnetic resonance.
  • Blood glucose and lactate levels, and tumor-associated macrophage (TAM) populations (M1/M2 phenotype) were quantified.

Main Results:

  • The combination of DCA and MTF did not significantly alter LLC/R9 tumor growth or metastasis indices compared to controls.
  • No significant changes were observed in mitochondrial function, circulating glucose/lactate levels, or protein nitrosylation.
  • A significant reduction in total TAMs was noted in tumors treated with MTF alone and in combination with DCA, but without altering M1/M2 subset distribution.

Conclusions:

  • DCA combined with MTF demonstrated no significant antitumor effect on LLC growth and metastasis in vivo at the tested doses.
  • The lack of efficacy correlated with unchanged mitochondrial function, metabolic markers, and TAM populations.
  • The study suggests that the potential antitumor activity of DCA and MTF may involve both local and systemic effects, which were not sufficiently modulated in this model.

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K